Acorda Therapeutics (NASDAQ:ACOR) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a note issued to investors on Sunday. The firm set a “buy” rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Price Performance

The company has a 50-day moving average of $11.13 and a 200-day moving average of $12.16. The company has a current ratio of 0.33, a quick ratio of 0.26 and a debt-to-equity ratio of 3.07. The firm has a market cap of $820,000.00, a PE ratio of 0.00 and a beta of 1.40. Acorda Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $24.20.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.